Julius Chapiro, MD/PhD
Associate Professor of Radiology and Biomedical ImagingCards
Appointments
Additional Titles
Associate Professor , Digestive Diseases
Associate Professor , Biomedical Engineering
Principal Investigator, Yale Interventional Oncology Laboratory , Radiology & Biomedical Imaging
Director, Center for Minimally Invasive Therapies, Radiology & Biomedical Imaging
Associate Director, Clinical and Translational Core, Liver Center
Contact Info
Appointments
Additional Titles
Associate Professor , Digestive Diseases
Associate Professor , Biomedical Engineering
Principal Investigator, Yale Interventional Oncology Laboratory , Radiology & Biomedical Imaging
Director, Center for Minimally Invasive Therapies, Radiology & Biomedical Imaging
Associate Director, Clinical and Translational Core, Liver Center
Contact Info
Appointments
Additional Titles
Associate Professor , Digestive Diseases
Associate Professor , Biomedical Engineering
Principal Investigator, Yale Interventional Oncology Laboratory , Radiology & Biomedical Imaging
Director, Center for Minimally Invasive Therapies, Radiology & Biomedical Imaging
Associate Director, Clinical and Translational Core, Liver Center
Contact Info
About
Titles
Associate Professor of Radiology and Biomedical Imaging
Associate Professor , Digestive Diseases; Associate Professor , Biomedical Engineering; Principal Investigator, Yale Interventional Oncology Laboratory , Radiology & Biomedical Imaging; Director, Center for Minimally Invasive Therapies, Radiology & Biomedical Imaging; Associate Director, Clinical and Translational Core, Liver CenterBiography
Dr. Chapiro is an Associate Professor in Radiology, Digestive Diseases (Hepatology) and in Biomedical Engineering, Principal Investigator of the Yale Interventional Oncology Research Lab and Director of the Center for Minimally Invasive Therapies. After graduating from the University of Leipzig and upon completion of his research thesis at the Justus-Liebig University in Giessen with summa cum laude, he served as a postdoctoral research fellow in interventional oncology at The Johns Hopkins Hospital and then as radiology resident at the Department of Radiology, Charité University Hospital in Berlin. He joined the Department of Radiology and Biomedical Imaging in 2016 as a research scientist and interventional radiology resident from Berlin, Germany.
Dr. Chapiro’s research focuses on developing new quantitative imaging biomarkers for the diagnosis, characterization, and therapeutic management of liver cancer. His translational research portfolio includes the development of novel embolic agents as well as the application of artificial intelligence solutions for the management of liver cancer. His basic research interest mainly focuses on developing new tools to characterize the tumor microenvironment and the immune system in the setting of loco-regional, image-guided therapies of liver cancer.
Creating innovative and clinically applicable imaging solutions for liver cancer with advanced molecular imaging, image post-processing and machine learning approaches and translating them to clinical practice has been his central mission for the past decade. He authored and co-authored >150 original research articles, reviews and book chapters and gave more than 100 talks and invited lectures within the last seven years. His research has also resulted in several patents, 510(k)-approved medical products and significant grant support from federal, foundational and industry sources. He is an active research mentor to more than 50 undergraduate, medical and graduate students as well as peers both at Yale and other national and international institutions. Being an active contributor, journal-, abstract- and grant reviewer in several professional societies (RSNA, SIR and SIO), he is also committed to education and the mission of disseminating research data and scientific knowledge. Dr. Chapiro consults the Editorial Board of the Journal of Hepatology and Radiology (RSNA), is a member of the American College of Radiology Liver Imaging Reporting and Data System (LI-RADS) Steering Committee, he additionally chairs the Grant Committee of the Society of Interventional Oncology and is the Chair of the Annual Meeting Program Planning Committee for the Subspecialty of Interventional Radiology at the Annual Radiological Society of North America meeting 2021-2023. He is the co-initiator of the "Rising Star" Student Exchange Program in collaboration with the Charité University Hospital in Berlin and directs the Center for Minimally Invasive Therapies. Dr. Chapiro is the Associate Director of the Clinical and Translational Core of the Yale Liver Center.
Appointments
Radiology & Biomedical Imaging
Associate Professor on TermPrimaryBiomedical Engineering
Associate Professor on TermSecondaryDigestive Diseases
Assistant ProfessorSecondary
Other Departments & Organizations
Education & Training
- Interventional Radiology Resident
- Yale New Haven Hospital
- Diagnostic Radiology Resident
- Charité Universitätsmedizin Berlin
- Research Fellow in Interventional Oncology
- The Johns Hopkins Hospital
- MD/PhD
- University of Leipzig
Research
Overview
Medical Subject Headings (MeSH)
- View Lab Website
Yale Interventional Oncology Research Laboratory
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
MingDe Lin, PhD
Todd Schlachter, MD
James Duncan, PhD
Fabian Max Laage Gaupp, MD
David C. Madoff, MD
Lawrence Staib, PhD
Carcinoma, Hepatocellular
Magnetic Resonance Imaging
Liver
Image Processing, Computer-Assisted
Neoplasm Staging
Artificial Intelligence
Publications
2024
Tumor response assessment in hepatocellular carcinoma treated with immunotherapy: imaging biomarkers for clinical decision-making
Sobirey R, Matuschewski N, Gross M, Lin M, Kao T, Kasolowsky V, Strazzabosco M, Stein S, Savic L, Gebauer B, Jaffe A, Duncan J, Madoff D, Chapiro J. Tumor response assessment in hepatocellular carcinoma treated with immunotherapy: imaging biomarkers for clinical decision-making. European Radiology 2024, 1-11. PMID: 39033181, DOI: 10.1007/s00330-024-10955-6.Peer-Reviewed Original ResearchConceptsMedian overall survivalTumor response criteriaTumor response assessmentHepatocellular carcinoma patientsHepatocellular carcinomaTumor responseOverall survivalResponse criteriaResponse assessmentNon-respondersPoorer median overall survivalPrediction of tumor responsePredictive valueHepatocellular carcinoma immunotherapyDisease controlPrognostic of survivalClinical baseline parametersLog-rank testKaplan-Meier curvesMultivariate Cox regressionPredicting overall survivalCox regression modelsSurvival benefitStratify patientsMRI pre-Outcomes of Repeat Conventional Transarterial Chemoembolization in Patients with Liver Metastases
Ghabili K, Windham-Herman A, Konstantinidis M, Murali N, Borde T, Adam L, Laage-Gaupp F, Lin M, Chapiro J, Georgiades C, Nezami N. Outcomes of Repeat Conventional Transarterial Chemoembolization in Patients with Liver Metastases. Annals Of Hepatology 2024, 101529. PMID: 39033928, DOI: 10.1016/j.aohep.2024.101529.Peer-Reviewed Original ResearchConceptsConventional transarterial chemoembolizationLiver metastasesNeuroendocrine tumorsColorectal carcinomaTransarterial chemoembolizationOverall survivalLung cancerAssociated with improved patient survivalManagement of liver metastasesMetastatic liver lesionsSingle-institution analysisNonresponding patientsSurvival outcomesPatient survivalResponse assessmentTarget lesionsMetastasisLiver lesionsPatientsResponse rateChemoembolizationSurvivalLiverLesionsCancerAutomated graded prognostic assessment for patients with hepatocellular carcinoma using machine learning
Gross M, Haider S, Ze’evi T, Huber S, Arora S, Kucukkaya A, Iseke S, Gebauer B, Fleckenstein F, Dewey M, Jaffe A, Strazzabosco M, Chapiro J, Onofrey J. Automated graded prognostic assessment for patients with hepatocellular carcinoma using machine learning. European Radiology 2024, 1-13. PMID: 38536464, DOI: 10.1007/s00330-024-10624-8.Peer-Reviewed Original ResearchAltmetricConceptsContrast-enhanced magnetic resonance imagingMagnetic resonance imagingClinical staging systemTime of diagnosisHepatocellular carcinomaClinical dataMortality risk predictionOverall survivalStaging systemRadiomic featuresManagement of hepatocellular carcinomaPersonalized follow-up strategiesAssociated with OSMethodsThis retrospective studyHepatocellular carcinoma patientsBaseline magnetic resonance imagingMRI radiomics featuresIndependent validation cohortHarrell's C-indexRisk predictionFollow-up strategiesHigh-risk groupPredictive risk scoreRadiomics feature extractionMedian timeHigh‐resolution extracellular pH imaging of liver cancer with multiparametric MR using Deep Image Prior
Dong S, Shewarega A, Chapiro J, Cai Z, Hyder F, Coman D, Duncan J. High‐resolution extracellular pH imaging of liver cancer with multiparametric MR using Deep Image Prior. NMR In Biomedicine 2024, 37: e5145. PMID: 38488205, DOI: 10.1002/nbm.5145.Peer-Reviewed Original ResearchConceptsDeep Image PriorU-NetUnsupervised deep learning techniquesU-Net parametersDeep learning techniquesHigh-resolution ground truthU-Net architectureSuper-resolution imagingImage priorsSuper-resolutionGround truthMean absolute errorDeepSpatial resolutionPostprocessing methodDeep imagingAbsolute errorImagesAnatomical MR imagesMR spectroscopic imagingAnatomical informationSpectroscopic imagingInformationAcquisition timeErrorEffect of Incomplete Cryoablation and Matrix Metalloproteinase Inhibition on Intratumoral CD8+ T-Cell Infiltration in Murine Hepatocellular Carcinoma.
Shewarega A, Santana J, Nam D, Berz A, Tefera J, Kahl V, Mishra S, Coman D, Duncan J, Roberts S, Wetter A, Madoff D, Chapiro J. Effect of Incomplete Cryoablation and Matrix Metalloproteinase Inhibition on Intratumoral CD8+ T-Cell Infiltration in Murine Hepatocellular Carcinoma. Radiology 2024, 310: e232365. PMID: 38349244, PMCID: PMC10902598, DOI: 10.1148/radiol.232365.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsT cell infiltrationCD8<sup>+</sup> T cellsMatrix metalloproteinase inhibitionT cellsHepatocellular carcinomaMatrix metalloproteinase inhibitorsMatrix metalloproteinasesResidual tumorCXCR3<sup>+</sup> CD8<sup>+</sup> T cellsCytotoxic CD8<sup>+</sup> T cell infiltrationIntratumoral CD8+ T cell infiltrationCD8+ T cell infiltrationCD8<sup>+</sup> T cell infiltrationMouse model of hepatocellular carcinomaEarly-stage hepatocellular carcinomaImage-guided tumor ablationUnpaired Student's <i>t</i> testModel of hepatocellular carcinomaFirst-line therapyMurine hepatocellular carcinomaT cell subsetsTumor-associated macrophagesMurine HCC modelLocal immune responseFemale BALB/c miceAtezolizumab and bevacizumab in combination with TACE for patients with BCLC B HCC.
Stein S, Cheng W, Wiess C, Pollak J, Perez Lozada J, Chapiro J, Madoff D. Atezolizumab and bevacizumab in combination with TACE for patients with BCLC B HCC. Journal Of Clinical Oncology 2024, 42: tps584-tps584. DOI: 10.1200/jco.2024.42.3_suppl.tps584.Peer-Reviewed Original ResearchConceptsRates of grade 3Grade 3Child-Pugh A cirrhosisBCLC-B HCCCombination of atezolizumabCurative intent therapyMain portal veinRisk of bleedingDiagnosis of HCCSignificant autoimmune diseaseSingle arm pilot studyB HCCECOG PSEffective regimenOpen-labelOverall survivalGastroesophageal varicesIntent therapyPredicted probabilityAutoimmune diseasesHepatic arteryPortal veinHepatic encephalopathyPatientsImprove outcomesAutomated MRI liver segmentation for anatomical segmentation, liver volumetry, and the extraction of radiomics
Gross M, Huber S, Arora S, Ze’evi T, Haider S, Kucukkaya A, Iseke S, Kuhn T, Gebauer B, Michallek F, Dewey M, Vilgrain V, Sartoris R, Ronot M, Jaffe A, Strazzabosco M, Chapiro J, Onofrey J. Automated MRI liver segmentation for anatomical segmentation, liver volumetry, and the extraction of radiomics. European Radiology 2024, 34: 5056-5065. PMID: 38217704, PMCID: PMC11245591, DOI: 10.1007/s00330-023-10495-5.Peer-Reviewed Original ResearchCitationsAltmetricConceptsMagnetic resonance imagingRadiomics feature extractionLiver volumetryIntraclass correlation coefficientRadiomic featuresLiver segmentationAutomated liver volumetryHepatocellular carcinoma patientsMann-Whitney U testAutomated liver segmentationManual segmentationQuantitative imaging biomarkersCarcinoma patientsRetrospective studyInstitutional databaseAnatomical localizationClinical relevanceManual volumetryMann-WhitneyU testExternal validationInternal test setImaging biomarkersInclusion criteriaResultsIn total
2023
Correction to: Consensus report from the 10th Global Forum for Liver Magnetic Resonance Imaging: developments in HCC management
Taouli B, Ba-Ssalamah A, Chapiro J, Chhatwal J, Fowler K, Kang T, Knobloch G, Koh D, Kudo M, Lee J, Murakami T, Pinato D, Ringe K, Song B, Tabrizian P, Wang J, Yoon J, Zeng M, Zhou J, Vilgrain V. Correction to: Consensus report from the 10th Global Forum for Liver Magnetic Resonance Imaging: developments in HCC management. European Radiology 2023, 34: 4845-4846. PMID: 38112766, PMCID: PMC11213717, DOI: 10.1007/s00330-023-10484-8.Peer-Reviewed Original ResearchCorrection: Consensus report from the 10th global forum for liver magnetic resonance imaging: multidisciplinary team discussion
Taouli B, Ba-Ssalamah A, Chapiro J, Chhatwal J, Fowler K, Kang T, Knobloch G, Koh D, Kudo M, Lee J, Murakami T, Pinato D, Ringe K, Song B, Tabrizian P, Wang J, Yoon J, Zeng M, Zhou J, Vilgrain V. Correction: Consensus report from the 10th global forum for liver magnetic resonance imaging: multidisciplinary team discussion. European Radiology 2023, 34: 724-725. PMID: 37930413, PMCID: PMC10791959, DOI: 10.1007/s00330-023-10342-7.Peer-Reviewed Original ResearchEthiodized oil as an imaging biomarker after conventional transarterial chemoembolization
Mendiratta-Lala M, Aslam A, Bai H, Chapiro J, De Baere T, Miyayama S, Chernyak V, Matsui O, Vilgrain V, Fidelman N. Ethiodized oil as an imaging biomarker after conventional transarterial chemoembolization. European Radiology 2023, 34: 3284-3297. PMID: 37930412, PMCID: PMC11126446, DOI: 10.1007/s00330-023-10326-7.Peer-Reviewed Original ResearchCitationsAltmetricConceptsConventional transarterial chemoembolizationTreatment response assessmentEthiodized oilHepatocellular carcinomaTransarterial chemoembolizationTreatment responseResponse assessmentIntermediate-stage hepatocellular carcinomaDuration of responsePortion of tumorPost-treatment imagingTissue drug concentrationsPost-treatment prognosisChemotherapy solutionLiver transplantationLocoregional therapyChemotherapy dosesCombination therapyStandard treatmentTherapy optionsTumor responseImaging appearancesIntraarterial embolizationTumor necrosisTumor vasculature
Clinical Care
Overview
Julius Chapiro, MD, is an interventional radiologist who specializes in treating patients with liver cancer. As a physician-scientist, his research focuses on developing new imaging biomarkers to diagnose, characterize, and treat liver cancer.
Dr. Chapiro’s works includes creating advanced molecular imaging methods and incorporating machine-learning approaches.
In addition to his clinical work and research, Dr. Chapiro is an associate editor for the Journal of Hepatology and a member of the American College of Radiology Liver Imaging Reporting and Data System (LI-RADS) Steering Committee. He is also the co-initiator of the Rising Star Student Exchange Program in collaboration with the Charité University Hospital in Berlin and co-directs the Yale Interventional Oncology Research Laboratory.
Dr. Chapiro is an assistant professor at Yale School of Medicine in Radiology, Digestive Diseases, and Biomedical Engineering. He is the associate director of the Clinical Core of the Yale Liver Center.
Clinical Specialties
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileLinks & Media
Media
News
- July 13, 2023Source: Yale Insights
Julius Chapiro: Minimally Invasive Liver Cancer Treatment
- May 22, 2023Source: Society of Interventional Radiology
The current and future role of artificial intelligence in interventional radiology
- December 21, 2021
Yale Liver Center Hosts Diamond Jubilee
- October 14, 2021
Dr. Julius Chapiro Shares Why He’s a Liver Cancer Physician/Scientist
Related Links
Get In Touch
Contacts
Events
Yale Only Julius Chapiro, MD/PhD